SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study

Figures & data

Table 1 Demographic Characteristics of the Russian Asthma Patients (n=618)

Characteristics	Mean (SD)	Median (Min-Max)	Number of Patients (%)
Age, years	54.4 (14.7)	57.0 (13.0–89.0)
Age groups, years
12–18			3 (0.5)
>18–54			261 (42.2)
≥55			354 (57.3)
Gender
Female			460 (74.4)
Male			158 (25.6)
BMI, kg/m2	28.5 (5.7)	28.0 (14.0–49.6)
BMI groups, kg/m2
<18.5			15 (2.4)
≥18.5–24.9			149 (24.1)
≥25–29.9			226 (36.6)
≥30.0			228 (36.9)
Smoking status
Active smoker			47 (7.6)
Former smoker			75 (12.1)
Never smoked			496 (80.3)

Table 2 Disease Characteristics of the Russian Asthma Patients (n=618)

Characteristics	Mean (SD)	Median (Min-Max)	Number of Patients (%)
Asthma duration, years	12.4 (10.5)	9.0 (1.0–67.0)
Number of severe exacerbations*	0.8 (1.2)	0.0 (0.0–12.0)
Groups with number of severe exacerbations*
0			327 (52.9)
1			190 (30.7)
2			65 (10.5)
3			26 (4.2)
>3			10 (1.6)
GINA step groups
Step 1			55 (8.9)
Step 2			78 (12.6)
Step 3			159 (25.7)
Step 4			261 (42.2)
Step 5			65 (10.5)
Level of asthma symptom control
Well-controlled			188 (30.4)
Partly controlled			207 (33.5)
Uncontrolled			223 (36.1)
Number of comorbidities
None			99 (16)
1–2			348 (56.3)
3–4			155 (25.1)
≥5			16 (2.6)

Note: *In the previous 12 months.

Table 3 Asthma Treatment Prescriptions in the Russian Asthma Patients (n=618)

Asthma Treatments in the Previous 12 Months	n (%)*
SABA alone	50 (8.1)
SABA as an add-on to maintenance therapy	453 (73.3)
ICS maintenance	72 (11.7)
ICS/LABA fixed-dose combination	503 (81.4)
OCS burst treatment/short course	215 (34.8)
OCS long-term/maintenance	20 (3.2)

Note: *Many patients were given different treatment modalities, which is why the sum total of all categories does not add up to 100% and the total number of patients enrolled in the study.

Figure 1 Number of SABA prescriptions in the previous 12 months by asthma severity in the Russian asthma patients (n=618).

Notes: The shares are calculated vis-à-vis the number of patients in a group, using available data on SABA prescriptions. Missing values are not shown in each group (in total n=59; 9.5%).

Figure 2 Number of additional SABA purchased without a prescription (canisters per year) by asthma severity in the Russian asthma patients (n=618). *The shares are calculated vis-à-vis the number of patients in a group, using with available data about SABA purchased OTC. Missing values are not shown in each group (in total n=24; 4%).